Mode
Text Size
Log in / Sign up
N/A Completed N=35 Treatment

Evaluation of Vision After Vivity IOL Implantation With a Target of Slight Myopia in the Non-dominant Eye

Source: ClinicalTrials.gov NCT04482439 ↗
Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcomePrimary: Binocular Near Visual Acuity — 0.14 logMAR

Summary

The objective is to assess binocular distance-corrected near (40 cm) visual acuity of patients after uneventful cataract surgery with bilateral implantation of the AcrySof® Vivity Intraocular lens (IOL) when the non-dominant eye is targeted for slight myopia.

Outcome Measures

OutcomeResultp-value
PRIMARY
Binocular Near Visual Acuity
0.14
SECONDARY
Prediction Accuracy
56
SECONDARY
Spectacle Independence
26
SECONDARY
Patient Spectacle Independence
23
SECONDARY
Number of Participants Rating Frequency of Visual Disturbances as "Never" or "Rarely"
19; 18; 13
SECONDARY
Manifest Refraction
.01; -.74
SECONDARY
Residual Cylinder
0.42
SECONDARY
Uncorrected Distance Visual Acuity
0.02
SECONDARY
Uncorrected Intermediate Visual Acuity
SECONDARY
Uncorrected Near Visual Acuity
0.12
SECONDARY
Corrected Distance Visual Acuity
0.01
SECONDARY
Distance Corrected Intermediate Visual Acuity
0.02

Eligibility Criteria

Inclusion Criteria

  • • Presenting for uncomplicated bilateral cataract surgery and have an interest in spectacle independence using an EDF IOL
  • Meet the requirements for on-label implantation of the EDF IOL
  • Gender: Males and Females.
  • Age: 40 or older.
  • Willing and able to provide written informed consent for participation in the study.
  • Willing and able to comply with scheduled visits and other study procedures.
  • Have good ocular health, with no pathology that compromises visual acuity (outside of residual refractive error and cataract)
  • Have regular corneal astigmatism with a magnitude that can be treated with a non-toric IOL or toric IOL.
  • Have 20/32 (0.2 logMAR) or better potential acuity in both eyes

Exclusion Criteria

  • • Irregular astigmatism (e.g. keratoconus)
  • Corneal pathology (e.g. scar, dystrophy, pterygium, severe dry eye)
  • Monocular status (e.g. amblyopia)
  • Previous radial keratotomy, corneal refractive surgery or other corneal surgery (e.g. corneal transplant, DSAEK, lamellar keratoplasty)
  • Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy)
  • Diabetic retinopathy
  • Macular pathology (e.g. ARMD, ERM)
  • History of retinal detachment
  • Subjects who have an unstable acute or chronic disease or illness that would confound the results of this investigation (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness), that are known to affect postoperative visual acuity.
  • Participation in any investigational drug or device trial within the previous 30 days prior to the start date of this trial (or currently participating).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04482439). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search